Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older, of any gender.
- People who have been diagnosed with a transformation of a specific type of lymphoma called Splenic Marginal Zone Lymphoma (SMZL) — this transformation may have been present at the time of the original SMZL diagnosis, or may have developed later during the course of the disease.
- People for whom stored tumour tissue samples (from the spleen, lymph nodes, other affected areas, blood, or bone marrow) collected at the time the transformation was diagnosed are available.
- People for whom medical records and follow-up information from diagnosis onwards are available.
Who may not be able to join:
- The trial lists no exclusion criteria at this time.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Luca Arcaini, MD, Fondazione IRCCS Policlinico San Matteo
Phone: +41 58 666 7321
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prevalence of mutations, copy number abnormalities and structural variants at SMZL diagnosis and at HT; Quantification and qualification of lesions acquired at the time of HT.; Prevalence of clonal relationship between SMZL and HT
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.